Aldeyra's eye drug fails piv­otal test in pa­tients with rare, in­flam­ma­to­ry dis­ease

Months af­ter eye drug de­vel­op­er Aldeyra Ther­a­peu­tics tast­ed Phase III suc­cess, it has stum­bled in an­oth­er late-stage study with its lead ex­per­i­men­tal drug.

The eye drops, re­prox­alap, are de­signed to work by di­min­ish­ing alde­hyde lev­els, which can con­tribute to in­flam­ma­tion. In the Phase III SO­LACE tri­al, the drug met nei­ther the pri­ma­ry end­point nor sec­ondary goals in pa­tients with non­in­fec­tious an­te­ri­or uveitis — a rare, se­vere, oc­u­lar in­flam­ma­to­ry dis­ease that can lead to blind­ness. The Lex­ing­ton, Mass­a­chu­setts-based drug de­vel­op­er did not dis­close the num­bers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.